DeepCyte launched with $1.5 million in seed funding to commercialize single-cell drug toxicity prediction, betting that single-cell metabolomics can improve how biopharma evaluates safety and mechanisms of toxicity. The company introduced MetaCore and DeeImmuno, positioning them for toxicity classification and biomarker and mechanism inference. DeepCyte’s approach uses MetaCore to generate atlas-scale, AI-ready single-cell metabolomics profiles and then applies DeeImmuno to predict toxicity outcomes from the resulting data. The company says it evaluated the system across 100 drugs and reported high accuracy for toxicity-mechanism prediction. The seed marks a notable early bet on single-cell safety analytics, an area that has been growing as developers seek earlier signal detection to reduce late-stage attrition.